Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Oncogene|March 8, 2016
Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancerQ Zhou, A D Abraham, L Li, et al.
Molecular Oncology|April 24, 2012
ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancerJohn J Arcaroli, Rebecca W Powell, Marileila Varella-Garcia, et al.
Clinical Cancer Drugs|January 12, 2019
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft ModelsAnna R Schreiber, Anna Nguyen, Stacey M Bagby, et al.
Oncotarget|September 17, 2017
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockadeThomas W Flaig, Maren Salzmann-Sullivan, Lih-Jen Su, et al.
Cancer Research|October 10, 2018
CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human MelanomaDinoop Ravindran Menon, Yuchun Luo, John J Arcaroli, et al.
Anti-Cancer Drugs|July 27, 2018
Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer modelsAnna Capasso, Todd M Pitts, Peter J Klauck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinibJohn J Arcaroli, Kevin S Quackenbush, Rebecca W Powell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer modelsM Pia Morelli, John J Tentler, Gillian N Kulikowski, et al.
Oncotarget|October 7, 2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenograftsChristopher H Lieu, Peter J Klauck, Patrick K Henthorn, et al.
Plos One|November 18, 2014
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerTodd M Pitts, Timothy P Newton, Erica L Bradshaw-Pierce, et al.
Pageof 5